During the past year, the data sciences team continued its focus on the creation of tools and analyses to answer specific questions in health-related problems.
For example, a multi-year collaboration with the IBRI, Eli Lilly and Company and the Indiana University School of Medicine culminated in a research study that highlights how electronic health records combined with biospecimens could predict possible comorbidities in persons living with diabetes.
The team also delivered a new platform to host electronic health records and disease-specific cohort data and variants where Eli Lilly and Company has placed two specific diabetes and cardiovascular cohorts for access by their scientists.
Other collaborations include understanding the effects of a specific medication type on the prevention of a cardiovascular condition, determining whether metformin has beneficial effects in autoimmune diseases, and identifying the rate of diabetic ketoacidosis in the initial diagnosis of type 1 diabetes patients.